No specific treatments are currently available for triple negative breast cancer (TNBC), a type of tumor that lacks the receptors targeted by many breast cancer therapies. Although many TNBC tumors lack two tumor suppressors, RB1 and p53, the specific downstream pathways that can be targeted as potential treatments for these tumors have not been identified. In this issue of the JCI, a team led by Eldad Zacksenhaus at Toronto General Research Institute discovered that the growth of TNBC-like breast tumors is supported by enhanced mitochondrial function. Mice carrying tumors that were deficient in both RB1 and p53 displayed upregulation of a pathway that controls the synthesis of mitochondrial proteins. They then identified an FDA-approved drug, tigecycline, that blocks this upregulation and reduces the growth of TNBC-like tumors in mice. This work suggests that inhibiting mitochondrial protein translation could potentially be a successful treatment for TNBC.
###
TITLE:
Targeting mitochondrial translation in RB1-deficient triple-negative breast cancer
AUTHOR CONTACT:
Eldad Zacksenhaus
Toronto General Research Institute
eldad.zacksenhaus@utoronto.ca
View this article at: http://www.jci.org/articles/view/81568?key=08bb64558861ecbad4d0
Journal
Journal of Clinical Investigation